3SU2

Crystal structure of NS3/4A protease variant A156T in complex with danoprevir

Summary for 3SU2

• Entry DOI: 10.2210/pdb3su2/pdb
• Related: 3SSN 3SU1 3SU2 3SU3 3SU4 3SU5 3SU6 3SUD 3SUE 3SUF 3SUG 3SV6 3SV7 3SV8 3SV9 3SYT 3SZ0 3SZC 3SZF 3SZG 3SZW 3T0K
• Descriptor: Genome polyprotein, (2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8 ,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate, SULFATE ION, ... (5 entities in total)
• Functional Keywords: ns3, drug resistance, drug design, protease inhibitors, hcv, serine protease, hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Hepatitis C virus subtype 1a; More
• Total number of polymer chains: 1
• Total formula weight: 22504.70

Authors

Schiffer, C.A.,Romano, K.P. (deposition date: 2011-07-11, release date: 2012-09-05, Last modification date: 2023-09-20)

• Primary citation: Romano, K.P.,Ali, A.,Aydin, C.,Soumana, D.,Ozen, A.,Deveau, L.M.,Silver, C.,Cao, H.,Newton, A.,Petropoulos, C.J.,Huang, W.,Schiffer, C.A.; The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors.; Plos Pathog., 8:e1002832-e1002832, 2012; PubMed: 22910833; DOI: 10.1371/journal.ppat.1002832

Experimental method

X-RAY DIFFRACTION (1.496 Å)